177Lu-DOTA-EB-TATE for Neuroendocrine Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new targeted radiation therapy for patients with advanced or hard-to-remove GEP-NETs. The therapy uses a radioactive substance that binds to cancer cells and delivers radiation directly to them.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot use somatostatin or its analogues within 4 months of the treatment, and short-acting octreotide must be stopped 24 hours before and after the treatment.
Is 177Lu-DOTA-EB-TATE safe for humans?
What makes the drug 177Lu-DOTA-EB-TATE unique for treating neuroendocrine cancer?
What data supports the effectiveness of the treatment 177Lu-DOTA-EB-TATE for neuroendocrine cancer?
Who Is on the Research Team?
Lisa Bodei
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Adults over 18 with advanced, inoperable well-differentiated neuroendocrine tumors (GEP-NETs) that are positive for somatostatin receptors can join this trial. They must have measurable disease, agree to use contraception, and have not had certain recent treatments or other cancers. People with severe organ dysfunction, active infections like hepatitis or HIV, uncontrolled diabetes, or who are pregnant/breastfeeding cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles, with dose escalation from 50 mCi to 150 mCi
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 177Lu-DOTA-EB-TATE
Find a Clinic Near You
Who Is Running the Clinical Trial?
Molecular Targeting Technologies, Inc.
Lead Sponsor
ClinSmart
Industry Sponsor